ONCAlert | Upfront Therapy for mRCC
Videos  >  

Analyzing the Data for Entrectinib in ROS1 TKI-Naive Patients With NSCLC

Alexander Drilon, MD
Published Online:6:24 PM, Thu June 6, 2019

Alexander Drilon, MD, clinical director, Early Drug Development Service, and associate professor of the Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the data examining the role of entrectinib in patients with non–small cell lung cancer who are naïve to treatment with a ROS1 tyrosine kinase inhibitor.

Looking at treatment-naïve patients with ROS1 fusion–positive lung cancers, this trial had more than 50 patients, all of which had a ROS1 fusion detected by either fluorescence in situ hybridization or next-generation sequencing. Topline results in terms of activity showed the objective response rate was high at 77%, Drilon says. The majority of patients had disease regression with this agent and also experienced some deep and durable responses. This is something you hope to see with an active targeted therapeutic, Drilon comments.

Drilon also notes that previous experience in this patient population does not show any response with entrectinib; therefore, the findings from this trial are important because entrectinib is not only a CNS-active agent, but it is also considered more of an early-generation ROS1 inhibitor.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.